MG
NYMX

Michael Gelband’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Michael Gelband’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-73,781
Closed -$117K – 2825
2021
Q2 		$117K Buy
+73,781
New +$137K ﹤0.01% 2118
2020
Q2 		– Sell
-56,618
Closed -$132K – 2104
2020
Q1 		$132K Sell
56,618
-41,507
-42% -$116K 0.01% 851
2019
Q4 		$216K Buy
+98,125
New +$194K ﹤0.01% 1309

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's NYMX Position: Q3 2021 in Review

Michael Gelband sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2021, closing a stake of 73,781 shares — an estimated $117K sold.

Michael Gelband first reported a position in NYMX in Q4 2019 and held it in 3 quarters. The position peaked at $216K in Q4 2019. 38 funds tracked by Wall St. Rank hold NYMX as of Q3 2021.

  • Michael Gelband reported no remaining Nymox Pharmaceutical Corp position as of Q3 2021 after selling out during the quarter.
  • Michael Gelband sold 73,781 Nymox Pharmaceutical Corp shares in Q3 2021, an estimated $117K.
  • Michael Gelband first reported a position in Nymox Pharmaceutical Corp in Q4 2019 and held it in 3 quarters.
  • Michael Gelband's Nymox Pharmaceutical Corp position peaked at $216K in Q4 2019.
  • 38 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.